A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

Eli Lilly announced that its obesity therapy Zepbound delivered superior outcomes versus Novo Nordisk’s Wegovy across five ...

By the end of the trial, those who took Zepbound lost about 20% of their body weight on average, compared with a nearly 14% ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...